Hepatitis B News and Research

Latest Hepatitis B News and Research

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

George Higginson Professor to receive 2010 Warren Alpert Foundation Prize

Howard Green, a founding father of regenerative medicine and the George Higginson Professor of Cell Biology at Harvard Medical School, will receive the 2010 Warren Alpert Foundation Prize for developing methodologies leading directly to permanent skin restoration therapy which is saving the lives of thousands of burn patients around the world.

22 Sep 2010

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

Philadelphia Inquirer: Efforts by N.J. Senate Democrats to restore $7.5 million to state family planning health centers ended Monday without any Republican support. In a 23-17 party line vote the Senate failed veto the governor's veto of center funding. Gov. "Christie's budget eliminated state funding to 58 family-planning health centers across the state, which last year provided services to more than 130,000 men and women, most of whom were underinsured.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

Biomagnetics signs merger agreement with Zhuhai Energy Science and Technology

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, recently announced its management team was flying to China to close its merger with Zhuhai Energy Science and Technology. Biomagnetics Diagnostics is pleased today to announce the signing of the formal merger agreement. All necessary governmental approvals are expected to be completed mid-week.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

Immunotherapy accepted for coverage in MEDLINE®

Future Medicine Ltd announced today that its journal Immunotherapy (ISSN 1750-743X) has been selected for coverage in MEDLINE®. Maintained by the U.S. National Library of Medicine, MEDLINE® (Medical Literature Analysis and Retrieval System Online) is a premier bibliographic database containing approximately 13 million references to journal articles in life sciences.

19 Sep 2010

Anthem Blue Cross hosts Hmong Health Awareness Fair with local health and community agencies

Tomorrow, Anthem Blue Cross State Sponsored Business will team with local health and community agencies to host the Hmong Health Awareness Fair. Local health and community organizations will be on hand to provide local families free health screenings, vaccines and health information. The health fair will take place from 9:00 a.m. to 3: p.m. at the Asian Village Shopping Center located at 4903 E. Kings Canyon Road.

18 Sep 2010

CDC, Epocrates educate healthcare professionals about safe injection practices

The Centers for Disease Control and Prevention and Epocrates, Inc. are educating healthcare professionals about safe injection practices conveniently and effectively on their smartphone devices. Epocrates' EssentialPoints mobile detailing program provides healthcare professionals with key lessons that can be applied directly to patient care.

18 Sep 2010

Vital Therapies expands SILVER clinical trial to Middle East

Vital Therapies, Inc., is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia in the further expansion of its SILVER clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure.

17 Sep 2010

Johnson & Johnson, Crucell announce advanced negotiations for potential public offer

Johnson & Johnson and Crucell N.V. today announced that they are in advanced negotiations for a potential public offer by Johnson & Johnson or an affiliate for all outstanding ordinary shares of Crucell not already held by Johnson & Johnson and its affiliates.

17 Sep 2010

Doctors demonstrate the true impact of vaccination

With Children Back in School, Doctors Clear up Confusion and Demonstrate the True Impact of Vaccination

16 Sep 2010

AAPCHO launches campaign to raise chronic hepatitis B awareness

The U.S. Department of Health and Human Services' Office of Minority Health, the Hepatitis B Foundation and the Association of Asian Pacific Community Health Organizations (AAPCHO) today launched a new campaign to raise awareness of the epidemic of chronic hepatitis B among Americans of Asian and Pacific Islander heritage.

15 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

Alice Cepeda receives National Award of Excellence in Research for Hispanic drug abuse research

The National Hispanic Science Network on Drug Abuse awarded the National Award of Excellence in Research by a New Investigator to Alice Cepeda, sociology professor and associate director of the Center for Drug and Social Policy Research, Graduate College of Social Work, University of Houston. Cepeda will be honored Sept. 30 at the organization's annual conference in New Orleans.

14 Sep 2010

AskBio enters patent license agreement with Pfizer for HCV therapy

Asklepios BioPharmaceutical, Inc., a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV).

14 Sep 2010

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

Hepatitis B News and Research

Latest Hepatitis B News and Research

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

George Higginson Professor to receive 2010 Warren Alpert Foundation Prize

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Biomagnetics signs merger agreement with Zhuhai Energy Science and Technology

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Immunotherapy accepted for coverage in MEDLINE®

Anthem Blue Cross hosts Hmong Health Awareness Fair with local health and community agencies

CDC, Epocrates educate healthcare professionals about safe injection practices

Vital Therapies expands SILVER clinical trial to Middle East

Johnson & Johnson, Crucell announce advanced negotiations for potential public offer

Doctors demonstrate the true impact of vaccination

AAPCHO launches campaign to raise chronic hepatitis B awareness

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Alice Cepeda receives National Award of Excellence in Research for Hispanic drug abuse research

AskBio enters patent license agreement with Pfizer for HCV therapy

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Hepatitis B News and Research

Latest Hepatitis B News and Research

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in